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Construction	  of	  3,5-­‐Dinitrated	  1,4-­‐Dihydropyridines	  Modifiable	  at	  
1,4-­‐Positions	  by	  a	  Reaction	  of	  β-­‐Formyl-­‐β-­‐nitroenamines	  with	  
Aldehydes	  	  
Haruyasu	  Asahara,*ab	  Mai	  Hamada,a	  Yumi	  Nakaike,a†	  and	  Nagatoshi	  Nishiwaki*ab	  
A	  novel	  and	  efficient	  method	  for	  the	  synthesis	  of	  4-­‐substituted	  3,5-­‐dinitro-­‐1,4-­‐dihydropyridines	  by	  a	  reaction	  of	  β-­‐formyl-­‐
β-­‐nitroenamines	   with	   aldehydes	   was	   developed.	   The	   reaction	   of	   nitroenamines	   with	   aldehydes	   leading	   to	   1,4-­‐
dihydropyridines	   and	   the	   self-­‐condensation	   of	   nitroenamines	   leading	   to	   pyridinium	   salt	   intermediate	   proceed	  
competitively.	   The	   obtained	   3,4,5-­‐trisubstituted-­‐1,4-­‐dihydropyridines	   readily	   transformed	   into	   the	   corresponding	  
pyridines	  in	  high	  yields.	  
Introduction	  
1,4-­‐Dihydropyridine	   (DHP)	   derivatives	   have	   attracted	   great	  
attention	   in	   the	   medicinal	   chemistry	   and	   pharmacological	  
fields	  due	   to	   their	  wide	   spectrum	  of	  bioactivities.1	   4-­‐Arylated	  
DHPs	  are	  often	  found	  as	  the	  fundamental	  framework	  in	  drugs	  
such	   as	   calcium	   antagonists2	   and	   also	   the	   drugs	   for	  
cardiovascular	  diseases.3	  Moreover,	  dimeric	  DHPs	  are	  used	  as	  
precursors	   for	   HIV-­‐1	   protease	   inhibitors.4	   Apart	   from	   their	  
medicinal	  value,	  DHPs,	  especially	  2,6-­‐unsubstituted	  DHPs	  with	  
electron-­‐withdrawing	   groups	   at	   the	   3-­‐	   and	   5-­‐positions,	   have	  
been	  employed	  as	  photoelectronic	  functional	  materials.5	  Thus,	  
numerous	   methods	   for	   the	   preparation	   of	   DHPs	   have	   been	  
reported.	   The	  Hantzsch	   reaction,	   a	  multi-­‐component	   reaction	  
of	  an	  aldehyde,	   two	  β-­‐keto	  esters,	  and	  ammonia,	   is	   the	  most	  
widely	   used.6	   However,	   only	   a	   few	   cases	   of	   the	   synthesis	   of	  
2,6-­‐unsubstituted	  3,5-­‐functionalized	  DHPs	  have	  been	  reported	  
so	  far;	   in	  particular,	   the	   introduction	  of	  nitro	  groups	  at	  the	  3-­‐	  
and	   5-­‐positions	   is	   quite	   difficult,	   mainly	   because	   of	   poor	  
reactivity.	  
Considering	   this	   background,	   we	   recently	   developed	   a	  
novel	   method	   for	   the	   construction	   of	   4-­‐arylated	   3,5-­‐dinitro-­‐
1,4-­‐dihydropyridines	   (dinitro-­‐DHPs)	   (Scheme	   1(a))7	   by	  
electrophilic	   substitution	   of	   electron-­‐rich	   benzene	   derivatives	  
with	   pyridinium	   ion	   X,	   formed	   by	   self-­‐condensation	   of	   β-­‐
formyl-­‐β-­‐nitroenamine	   1.	   The	   formylnitroenamine	   1	   is	   useful	  
synthetic	   unit	   because	   its	   versatile	   reactivity	   arises	   from	   two	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withdrawing	   nitro	   group.	   It	   is	   easily	   prepared	   from	  
commercially	   available	   reagents	  by	  a	   few	   steps,	   and	   they	  are	  
easily	   handled	   because	   of	   the	   high	   solubility	   in	   common	  
organic	   solvents.	   Although	   this	   reaction	   affords	   dinitro-­‐DHPs	  
that	   are	   not	   easily	   formed	   by	   other	   methods,	   the	   substrate	  
scope	   is	   limited	   to	   highly	   electron-­‐rich	   aromatics.	   Thus,	   the	  
development	   of	   an	   efficient	   method	   for	   the	   synthesis	   of	  
dinitro-­‐DHPs	  having	  various	  groups	  is	  highly	  desirable.	  
Based	   on	   the	   Hantzsch	   DHP	   synthesis,8	   which	   includes	   a	  
protonated	   α,β-­‐unsaturated	   ketone	   and	   an	   enamine	   as	   key	  
intermediates	   (Scheme	   1(b)),	   a	   multi-­‐component	   reaction	  
between	   two	  molecules	  of	  β-­‐formyl-­‐β-­‐nitroenamine	  1	   and	  an	  
aldehyde	   2	   is	   designed	   (Scheme	   1(c)).	   In	   this	   strategy,	   the	  
nitroenamine	  serves	  as	  both	  an	  α,β-­‐unsaturated	   iminium	  and	  
an	   enamine,	   enhancing	   the	   synthetic	   utility	   of	  
formylnitroenamine	   as	   a	   building	   block.	   Herein,	   we	   report	   a	  
new	  method	  for	  the	  construction	  of	  various	  4-­‐substituted	  3,5-­‐
dinitro-­‐1,4-­‐DHPs	   3	   and	   their	   oxidation	   to	   afford	   3,5-­‐
dinitropyridines.	  
Results	  and	  discussion	  	  
At	   first,	   we	   studied	   the	   reaction	   of	   N-­‐propyl-­‐β-­‐formyl-­‐β-­‐
nitroenamine	  1A	  (0.5	  mmol)	  with	  p-­‐tolualdehyde	  (Tol-­‐CHO)	  2a	  
under	   acidic	   conditions	   (Table	   1).	   When	   the	   reaction	   was	  
carried	   out	   in	   the	   presence	   of	   p-­‐toluenesulfonic	   acid	  
monohydrate	  (p-­‐TsOH·∙H2O,	  0.25	  mmol)	  in	  ethanol,	  the	  desired	  
4-­‐arylated	   dinitro-­‐DHP	   3Aa	   was	   successfully	   obtained	   in	   67%	  
yield	   (entry	   1,	   based	   on	   half	   of	   1A),	   accompanied	   by	   the	  
formation	  of	  4-­‐unsubstituted	  DHP	  4A	  (4%).	  Although	  the	  yield	  
of	   the	   desired	   product	   3Aa	   slightly	   increased	   up	   to	   78%	  
when0.5	   mmol	   of	   p-­‐TsOH	   was	   used,	   the	   yield	   of	   the	   by-­‐
product	  4A	  also	  increased	  (entry	  2).	  However,	  higher	  amounts	  
Table	  1	  Optimization	  of	  reaction	  conditions.	  
	  
a	  Determined	  by	  1H	  NMR.	  Based	  on	  1A.	  b	  Isolated	  yield	  was	  shown	  in	  parentheses.	  
	  
Scheme	  2	  Proposed	  mechanism	  for	  the	  formation	  of	  3,5-­‐dinitro-­‐DHPs	  4.	  
	  
of	  p-­‐TsOH	  did	  not	  significantly	  affect	  the	  reaction	  (entry	  3,	  for	  
additionaloptimizations	  see	  Supporting	  Information,	  Table	  S1).	  
As	   depicted	   in	   Scheme	   2,	   the	   4-­‐unsubstituted	   DHP	   4A	   was	  
formed	   by	   the	   reduction	   of	   the	   pyridinium	   ion	   X,	   which	   is	  
obtained	   by	   self-­‐condensation	   of	   1A	   in	   the	   absence	   of	  
aldehyde	  2	  (more	  details	  on	  the	  reduction	  of	  X	  by	  alcohol	  are	  
discussed	  later).From	  this	  viewpoint,	  increasing	  the	  amount	  of	  
aldehyde	   was	   assumed	   to	   be	   effective	   for	   suppressing	   the	  
competitive	   formation	   of	   the	   by-­‐product	   4A.	   Accordingly,	  
when	  2.5	  mmol	  of	  2a	  was	  used,	  the	  desired	  product	  3Aa	  was	  
successfully	   isolated	   in	   90%	   yield	   with	   negligible	   amounts	   of	  
4A	  (entry	  5).	  
With	   the	  optimal	   conditions	  being	  derived,	   the	   scope	  and	  
limitation	   of	   this	   reaction	   were	   examined	   using	   various	  
aromatic	  aldehydes	  2b–e	  (Table	  2).	  In	  all	  cases,	  the	  desired	  4-­‐
arylated	   dinitro-­‐DHPs	   3	   were	   obtained	   in	   high	   yields.	   It	   is	  
noteworthy	   that,	   unlike	   previous	   methodologies,	   electron-­‐
neutral	  (entry	  2)	  and	  electron-­‐deficient	  aromatic	  rings	  (entries	  
3	  and	  4)	  could	  be	  introduced.	  
Table	  2	  Scope	  of	  the	  reaction	  with	  aromatic	  aldehydes.	  
	  
a	  Isolated	  yield.	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Table	  3	  Scope	  of	  the	  reaction	  with	  aliphatic	  aldehydes.	  
	  
a	   Determined	   by	   1H	   NMR.	   Based	   on	   1A.	   b	   Isolated	   yields	   were	   shown	   in	  
parentheses.	  c	  Based	  on	  aldehyde	  2.	  
Next,	   we	   examined	   the	   substrate	   scope	   using	   a	   more	  
reactive	  aliphatic	  aldehyde,	  i.e.,	  butanal	  2f	  (Table	  3).	  Although	  
the	   desired	   product	   3Af	   was	   obtained,	   the	   yield	   was	   lower	  
than	   that	   of	   4-­‐arylated	   DHPs	   3Aa–e,	   and	   the	   3,4-­‐dialkyl-­‐DHP	  
derivative	  5	   was	   also	   formed	   (entry	   1).	   Product	   5	   formed	   by	  
the	   Michael	   addition	   of	   the	   nitroenamine	   1A	   to	   the	   α,β-­‐
unsaturated	   enone	   that	   is	   formed	   by	   aldol	   condensation	   of	  
butanal	   2f	   (Scheme	   3).	   This	   competitive	   reaction	   was	  
suppressed	  by	  decreasing	  the	  amount	  of	  aldehyde	  2f,	  thereby	  
increasing	   the	   yield	   of	   dinitro-­‐DHP	   3Af	   up	   to	   45%,	  
accompanied	   by	   19%	   of	   unsubstituted	   product	   4A	   (entry	   2).	  
The	  undesired	  aldol	   reaction	  of	   the	  aldehyde	  was	  suppressed	  
by	   using	   the	   bulkier	   3-­‐methylbutanal	   2g,	   which	   successfully	  
afforded	  dinitro-­‐DHP	  3Ag	  in	  70%	  isolated	  yield	  (entry	  3).	  
In	   order	   to	   facilitate	   the	  modification	   at	   the	   1-­‐position	   of	  
the	   dinitro-­‐DHPs,	   application	   of	   the	   procedure	   optimized	   for	  
1A	  to	  N-­‐tert-­‐butyl-­‐β-­‐formyl-­‐β-­‐nitroenamine	  1B	  was	  attempted.	  
Nitroenamine	   1B	   reacted	   similarly	   with	   aromatic	   aldehydes	  
2a–e	  to	  afford	  the	  corresponding	  4-­‐arylated	  dinitro-­‐DHPs	  3Ba–
e	   in	  good	  yields	   (Table	  4,	  entries	  1-­‐5,	  Figure	  S1),	  whereas	  the	  
reaction	  with	  aliphatic	  aldehydes	  2f	  and	  2g	  gave	  3Bf	  and	  3Bg	  
	  
	  
Scheme	  3	  Undesired	  side	  reactions.	  
Table	  4	  Reaction	  of	  N-­‐tert-­‐butyl-­‐β-­‐formyl-­‐β-­‐nitroenamine	  1B	  with	  aldehydes.	  
	  
a	  Isolated	  yield	  
in	  low	  yields	  (entries	  6	  and	  7).	  It	  is	  noteworthy	  that,	  in	  all	  cases,	  
3,5-­‐dinitropyridine	   6	   was	   obtained	   in	   moderate	   yields.	   A	  
plausible	   mechanism	   for	   the	   formation	   of	   6	   is	   shown	   in	  
Scheme	  2.	  Upon	  treatment	  of	  1B	  with	  acid,	   two	  molecules	  of	  
1B	   underwent	   a	   formal	   [4	   +	   2]	   condensation	   to	   form	   the	  
pyridinium	   ion	   intermediate	   XB,	   from	   which	   the	   stable	   tert-­‐
butyl	  cation	  was	  eliminated	  to	  afford	  the	  3,5-­‐dinitropyridine	  6.	  
As	   expected,	   6	   was	   produced	   in	   70%	   yield	   when	   1B	   was	  
treated	  under	  the	  same	  conditions	  in	  the	  absence	  of	  aldehyde	  
2	   (entry	   8).	   The	   highly	   electron-­‐deficient	   heteroarene	   6	   is	   a	  
potentially	   useful	   and	   versatile	   synthetic	   intermediate;9	  
however,	   its	   conventionally	   used	   preparation	  method	   suffers	  
from	   troublesome	  multi-­‐step	   reactions	   and	   low	   total	   yield.10	  
Thus,	  our	   reaction	  using	  N-­‐tert-­‐butyl-­‐β-­‐formyl-­‐β-­‐nitroenamine	  
1B	  represents	  an	  alternative	  method	  for	  the	  rapid	  construction	  
of	  3,5-­‐dinitropyridine	  6	  in	  high	  yield.	  
In	   this	   method,	   in	   addition	   to	   4-­‐substituted	   DHPs	   3,	   4-­‐
unsubstituted	  DHPs	  4	  were	  obtained	  as	  by-­‐products.	   In	  order	  
to	   gain	   an	   insight	   into	   the	  mechanism	  of	   the	   formation	  of	   4-­‐
unsubstituted	   DHPs	   4,	   several	   control	   experiments	   were	  
conducted	   (Scheme	   4).	   When	   1A	   was	   treated	   with	   TsOH	   in	  
CD3CD2OD	   (ethanol-­‐d6),	   4-­‐monodeuterated	   3,5-­‐dinitro-­‐DHP	  
was	  obtained	  in	  55%	  yield	  along	  with	  10%	  of	  4-­‐CD3-­‐3,5-­‐dinitro-­‐
DHP	   (Scheme	   4(a)).	   Moreover,	   when	   benzyl	   alcohol	   was	  
employed	   as	   solvent	   instead	   of	   ethanol,	   4-­‐phenyl-­‐3,5-­‐dinitro-­‐
DHP	  3Ac	  and	  3,5-­‐dinitro-­‐DHP	  4	  were	  obtained	  in	  33%	  and	  66%	  
yields,	  respectively	  (Scheme	  4(b)).	  In	  addition,	  the	  formation	  of	  
benzaldehyde	  was	  confirmed	  by	  the	  1H	  NMR	  spectrum	  of	  the	  
reaction	  mixture.	  These	  observations	  obviously	   indicated	   that	  
the	  pyridinium	  ion	  X	  was	  reduced	  by	  the	  alcohol	  via	  formation	  
of	  the	  4-­‐position	  alcohol	  adduct	  intermediate	  Y	  (Scheme	  5).	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Scheme	  4	  Control	  experiments.	  
	  
Scheme	  5	  Formation	  of	  3,5-­‐dinitro-­‐DHPs	  3	  and	  4.	  
Subsequently,	   the	   transfer	   of	   the	   R	   group	   leads	   to	   4-­‐
substituted	   products	  3	   (route	   a),	   whereas	   the	   intramolecular	  
hydride	  transfer	  gives	  the	  reduced	  product	  4	  (route	  b).	  Herein,	  
the	  reduction	  of	  pyridinium	  ion	  by	  alcohol	  is	  often	  found	  in	  the	  
biological	  system,	  such	  as	  NAD+/NADH	  system	  in	  the	  presence	  
of	   dehydrogenase.11	   On	   the	   other	   hand,	   Lu	   et	   al.	   thoroughly	  
studied	   the	   mechanism	   of	   the	   reduction	   of	   pyridinium	   ion	  
derivatives	  by	  an	  alcohol	  in	  the	  presence	  of	  Brønsted	  acid	  and	  
showed	   the	   reaction	   involves	   intermolecular	   hydride	   transfer	  
as	   transition	   state	   similar	   to	   biological	   system.12	   Contrary	   to	  
these	  examples,	  our	  reaction	  is	  first	  example	  for	  the	  reduction	  
of	  pyridinium	  salt	  by	  alcohol	  via	  intramolecular	  hydride	  or	  alkyl	  
transfer	  mechanism.	  
With	   4-­‐arylated	   dinitro-­‐DHPs	   in	   hand,	   we	   carried	   out	  
preliminary	   studies	   on	   the	   oxidative	   conversion	   of	   4-­‐
substituted	   DHPs	   to	   4-­‐substituted-­‐3,5-­‐dinitropyridines,	   which	  
are	   not	   easily	   accessible	   by	   other	   methods.13	   As	   shown	   in	  
Scheme	  6,	  treatment	  of	  4-­‐anisyl	  DHP	  3Bb	  with	  excess	  amount	  
of	  NaNO2	  in	  chloroform	  under	  oxygen	  atmosphere	  at	  80	  °C	  for	  
24	   h	   to	   afford	   the	   desired	   product	   7	   in	   a	   promising	   isolated	  
yield	  of	  68%.	  The	  obtained	  4-­‐arylated-­‐3,5-­‐dinitropyridines	  are	  
useful	   synthetic	   intermediates	   for	   functional	   materials.	  
Moreover,	  the	  push-­‐pull	  electronic	  properties	  of	  this	  product	  	  
	  
	  
Scheme	  6	  Oxidation	  of	  N-­‐tert-­‐butyl-­‐3,5-­‐dinitro-­‐DHP	  3Bb.	  
	  
are	  crucial	   for	  developing	  organic	  materials	  with	  potential	  
applications	  in	  nonlinear	  optics.	  
	  
Conclusions	  
In	   conclusion,	   we	   have	   successfully	   developed	   a	   multi-­‐
component	   reaction	   of	   β-­‐formyl-­‐β-­‐nitroenamines	   1	   and	  
aldehydes	  2	   leading	   to	   the	   formation	  of	  diverse	  4-­‐substituted	  
3,5-­‐dinitro-­‐DHPs.	   This	   method	   provides	   an	   environmentally	  
benign	  and	  metal-­‐free	  access	  to	  a	  variety	  of	  2,6-­‐unsubstituted	  
3,5-­‐dinitro-­‐DHPs,	   which	   have	   not	   been	   extensively	   studied	  
because	  of	  the	  synthetic	  difficulties.	  From	  a	  mechanistic	  point	  
of	  view,	  competitively	  formed	  self-­‐condensed	  pyridinium	  ion	  X	  
showed	   interesting	   reactivity.	   Namely,	   alcohols	  
regioselectively	  attack	  to	  4-­‐position	  of	  intermediate	  X	  to	  form	  
adduct	  intermediate	  Y,	  and	  then	  is	  oxidized	  via	  intramolecular	  
hydride	  or	  alkyl	  transfer.	  This	  is	  first	  example	  for	  the	  reduction	  
of	   pyridinium	   salt	   by	   alcohol	   via	   intramolecular	   process.	   In	  
addition,	   the	   synthesized	   DHPs	   are	   easily	   transformed	   to	   4-­‐
substituted	  3,5-­‐dinitropyridines,	  which	  have	  high	  potential	  for	  
nonlinear	   optical	   materials.	   Further	   applications	   of	   the	  
electronic	  properties	  of	  the	  obtained	  products	  in	  this	  work	  are	  
currently	  underway.	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Experimental	  
General	  Procedure	  for	  the	  Reaction	  of	  N-­‐propyl-­‐β-­‐Formyl-­‐β-­‐
nitroenamines	  1A	  with	  p-­‐Tolualdehyde	  2a	  
p-­‐TsOH·∙H2O	  (95	  mg,	  0.5	  mmol)	  was	  added	  to	  the	  suspension	  of	  
β-­‐formyl-­‐β-­‐nitroenamine	  1A	  (0.5	  mmol)	  and	  p-­‐tolualdehyde	  2a	  
(306	  μL,	  2.5	  mmol)	  in	  ethanol	  (1	  mL),	  and	  the	  resultant	  mixture	  
was	  stirred	  at	  80	  °C	  for	  20	  h	  in	  a	  sealed	  tube.	  The	  solvent	  was	  
then	   evaporated	   in	   vacuo,	   and	   the	   residue	   was	   diluted	   with	  
CH2Cl2	   (20	   mL)	   and	   washed	   with	   water	   (10	   mL	   ×	   3).	   After	  
drying	   (MgSO4)	   and	   evaporation	   of	   the	   solvent,	   the	   residue	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was	   purified	   on	   silica	   gel	   column	   chromatography	  
(hexane/ethyl	   acetate	   =	   5/1).	   Further	   purification	   was	  
performed	   by	   recrystallization	   from	   chloroform.	   All	   reactions	  
of	  nitroenamines	  with	  aldehydes	  were	  conducted	  according	  to	  
general	   procedure.	   Compound	  3Ab	   is	   known	   and	   its	   spectral	  
data	  match	  with	  reported	  data.7  
General	  Procedure	  for	  the	  Synthesis	  of	  4-­‐Arylated-­‐3,5-­‐
Dinitropyridine	  7	  	  
The	   oxidation	   was	   performed	   according	   to	   literature	  
procedure.13	   To	   a	   suspension	   of	   3,5-­‐dinitro-­‐DHP	   3Bb	   (0.3	  
mmol,	   83	  mg)	   in	   acetic	   acid	   (3	  mL)	   and	   chloroform	   (0.5	  mL),	  
sodium	  nitrite	  (1.5	  mmol)	  was	  added.	  The	  mixture	  was	  stirred	  
under	  oxygen	  at	  80	   °C	   for	  24	  h	   in	  a	   sealed	   tube.	  The	  mixture	  
was	  then	  evaporated,	  and	  the	  residue	  was	  diluted	  with	  CH2Cl2	  
(20	   mL)	   and	   washed	   with	   water	   (10	   mL	   ×	   3).	   After	   drying	  
(MgSO4)	   and	   evaporation	   of	   the	   solvent,	   The	   residue	   was	  
purified	  by	  column	  chromatography	  on	  silica	  gel	  (hexane/ethyl	  
acetate	  =	  9/1).	  
1,4-­‐Dihydro-­‐3,5-­‐dinitro-­‐4-­‐(4-­‐methylphenyl)-­‐1-­‐propylpyridine	  (3Aa)	  	  
Orange	   solid	   (71.9	   mg,	   90%):	   mp	   182–184	   °C;	   1H	   NMR	   (400	  
MHz,	  CDCl3,	  30	  °C,	  TMS)	  δ	  1.07	  (t,	  J	  =	  7.2	  Hz,	  3H),	  1.85	  (tq,	  J	  =	  
7.2,	  7.2	  Hz,	  2H),	  2.29	  (s,	  3H),	  3.57	  (t,	  J	  =	  7.2	  Hz,	  2H)	  5.61	  (s,	  1H),	  
7.10	  (d,	  J	  =	  8.4	  Hz,	  2H),	  7.21	  (d,	  J	  =	  8.4	  Hz,	  2H),	  7.82	  (s,	  2H);	  13C	  
NMR	  (100	  MHz,	  CDCl3,	  30	  °C,	  TMS)	  δ	  10.7	  (CH3),	  21.1	  (CH),	  23.5	  
(CH2),	  39.3	  (CH3),	  57.6	  (CH2),	  128.3	  (CH),	  129.3	  (CH),	  133.6	  (C),	  
134.6	  (CH),	  137.5	  (C),	  137.9	  (C);	  IR	  (KBr/cm-­‐1)	  1672	  (C=C),	  1489,	  
1279	   (NO2).	   HRMS	   (EI,	   double	   focusing)	   m/z	   calcd.	   for	  
C15H17N3O4:	  303.1219,	  found	  303.1230.	  	  
1,4-­‐Dihydro-­‐3,5-­‐dinitro-­‐4-­‐phenyl-­‐1-­‐propylpyridine	  (3Ac)	  
Orange	   solid	   (60.1	   mg,	   84%):	   mp	   180–182	   °C;	   1H	   NMR	   (400	  
MHz,	  CDCl3,	  30	  °C,	  TMS)	  δ	  1.08	  (t,	  J	  =	  7.2	  Hz,	  3H),	  1.87	  (tq,	  J	  =	  
7.2,	  7.2	  Hz,	  2H),	  3.58	  (t,	  J	  =	  7.2	  Hz,	  2H)	  5.65	  (s,	  1H),	  7.23–7.35	  
(m,	  5H),	  7.84	  (s,	  2H)	  13C	  NMR	  (100	  MHz,	  CDCl3,	  30	  °C,	  TMS)	  δ	  
10.7	  (CH3),	  23.5	  (CH2),	  39.7	  (CH),	  57.6	  (CH2),	  128.1	  (CH),	  128.4	  
(CH),	  128.6	   (C),	   133.4	   (CH),	  134.7	   (C),	   140.3	   (C);	   IR	   (KBr/cm-­‐1)	  
1672	  (C=C),	  1489,	  1277	  (NO2).	  HRMS	  (EI,	  double	  focusing)	  m/z	  
calcd.	  for	  C14H15N3O4:	  289.1063,	  found	  289.1053.	  	  
4-­‐(4-­‐Chlorophenyl)-­‐1,4-­‐dihydro-­‐3,5-­‐dinitro-­‐1-­‐propylpyridine	  
(3Ad)	  	  
Orange	   solid	   (71.3	   mg,	   88%):	   mp	   143–144	   °C;	   1H	   NMR	   (400	  
MHz,	  CDCl3,	  30	  °C,	  TMS)	  δ	  1.08	  (t,	  J	  =	  7.2	  Hz,	  3H),	  1.88	  (tq,	  J	  =	  
7.2,	  7.2	  Hz,	  2H),	  3.59	  (t,	  J	  =	  7.2	  Hz,	  2H),	  5.64	  (s,	  1H),	  7.26–7.28	  
(m,	  4H),	  7.84	  (s,	  2H);	  13C	  NMR	  (100	  MHz,	  CDCl3,	  30	  °C,	  TMS)	  δ	  
10.7	  (CH3),	  23.5	  (CH2),	  39.3	  (CH),	  57.6	  (CH2),	  128.8	  (CH),	  129.7	  
(CH),	  133.1	   (C),	   134.1	   (CH),	  134.9	   (C),	   138.8	   (C);	   IR	   (KBr/cm-­‐1)	  
1674	  (C=C),	  1489,	  1279	  (NO2).	  HRMS	  (EI,	  double	  focusing)	  m/z	  
calcd.	  for	  C14H14ClN3O4:	  323.0673,	  found	  323.0670.	  
1,4-­‐Dihydro-­‐3,5-­‐dinitro-­‐4-­‐(4-­‐nitrophenyl)-­‐1-­‐propylpyridine	  
(3Ae)	  
Brown	   oil	   (66.9	   mg,	   80%);	   1H	   NMR	   (400	   MHz,	   CDCl3,	   30	   °C,	  
TMS)	   δ	   1.09	   (t,	   J	   =	   7.2	  Hz,	   3H),	   1.89	   (tq,	   J	  =	  7.2,	   7.2	  Hz,	   2H),	  
3.64	  (t,	  J	  =	  7.2	  Hz,	  2H)	  5.77	  (s,	  1H),	  7.53	  (d,	  J	  =	  8.4	  Hz,	  2H),	  7.90	  
(s,	  2H),	  8.17	  (d,	  J	  =	  8.4	  Hz,	  2H);	  13C	  NMR	  (100	  MHz,	  CDCl3,	  30	  °C,	  
TMS)	  δ	  10.7	  (CH3),	  23.5	  (CH2),	  39.9	  (CH3),	  57.8	  (CH2),	  123.9	  (CH),	  
129.5	   (CH),	   132.5	   (C),	   135.5	   (CH),	   146.9	   (C),	   147.6	   (C);	   IR	  
(KBr/cm-­‐1)	   1681	   (C=C),	   1506,	   1278	   (NO2).	   HRMS	   (EI,	   double	  
focusing)	  m/z	  calcd.	  for	  C14H14N4O6:	  334.0913,	  found	  334.0905.	  
1,4-­‐Dihydro-­‐3,5-­‐dinitro-­‐1,4-­‐dipropylpyridine	  (3Af)	  	  
Brown	   oil	   (25.6	   mg,	   40%);	   1H	   NMR	   (400	   MHz,	   CDCl3,	   30	   °C,	  
TMS)	  δ	  0.87	  (t,	  J	  =	  7.2	  Hz,	  3H),	  1.00	  (t,	  J	  =	  7.2	  Hz,	  3H),	  1.20	  (dt,	  J	  
=	  4.4,	  7.2	  Hz,	  2H),	  1.64	  (tq,	  J	  =	  7.2,	  7.2	  Hz,	  2H),1.76	  (tq,	  J	  =	  7.2	  ,	  
7.6	  Hz,	  2H)	  3.48	  (t,	  J	  =	  7.6	  Hz,	  2H),	  4.79	  (t,	  J	  =	  4.4	  Hz,	  1H),	  7.77	  
(s,	   2H);	   13C	   NMR	   (100	  MHz,	   CDCl3,	   30	   °C,	   TMS)	   δ	   10.6	   (CH3),	  
13.9	   (CH3),	   18.1	   (CH2),	   23.5	   (CH2),	   33.7	   (CH2),	   33.9	   (CH),	   57.5	  
(CH2),	   131.9	   (C),	   136.4	   (CH);	   IR	   (KBr/cm
-­‐1)	   1674	   (C=C),	   1506,	  
1277	   (NO2).	   HRMS	   (EI,	   double	   focusing)	   m/z	   calcd.	   for	  
C11H17N3O4:	  255.1219,	  found	  255.1213.	  
1,4-­‐Dihydro-­‐3,5-­‐dinitro-­‐4-­‐isobutyl-­‐1-­‐propylpyridine	  (3Ag)	  
Brown	   oil	   (47.1	   mg,	   70%);	   1H	   NMR	   (400	   MHz,	   CDCl3,	   30	   °C,	  
TMS)	  δ	  0.90	   (d,	   J	  =	  6.4	  Hz,	  6H),	  1.00	   (t,	   J	  =	  7.2	  Hz,	  3H),	  1.46–
1.49	   (m,	  2H),	  1.78	   (tq,	   J	  =	  7.2,	  7.2	  Hz,	  2H),	  3.53	   (t,	   J	  =	  7.2	  Hz,	  
2H),	  4.78	   (dt,	   J	  =	  0.8,	  5.2	  Hz,	  1H),	  7.76	   (d,	   J	  =	  0.8	  Hz,	  2H);	   13C	  
NMR	   (100	  MHz,	   CDCl3,	   30	   °C,	   TMS)	   δ	   10.6	   (CH3),	   23.1	   (CH3),	  
23.6	   (CH2),	   25.1	   (CH),	   31.8	   (CH),	   43.9	   (CH2),	   57.5	   (CH2),	   132.9	  
(C),	   136.1	   (CH);	   IR	   (KBr/cm-­‐1)	   1670	   (C=C),	   1506,	   1277	   (NO2).	  
HRMS	   (EI,	   double	   focusing)	   m/z	   calcd.	   for	   C12H19N3O4:	  
269.1376,	  found	  269.1385.	  	  
1,4-­‐Dihydro-­‐1,4-­‐dipropyl-­‐3-­‐ethyl-­‐5-­‐nitropyridine	  (5Af)	  	  
Brown	  oil;	  1H	  NMR	  (400	  MHz,	  CDCl3,	  30	  °C,	  TMS)	  δ	  0.87	  (t,	  J	  =	  
7.2	   Hz,	   3H),	   0.95	   (t,	   J	   =	   7.6	   Hz,	   3H),	   1.07	   (t,	   J	   =	   7.2	   Hz,	   3H),	  
1.10–1.21	  (m,	  2H),	  1.32–1.45	  (m,	  1H),	  1.60–1.70	  (m,	  2H),	  1.71–
1.80	  (m,	  1H),	  2.01–2.22	  (m,	  2H),	  3.23–3.33	  (m,	  2H),	  3.92	  (t,	  J	  =	  
4.0	  Hz,	  1H),	  5.72	  (s,	  1H),	  7.91	  (s,	  1H);	  13C	  NMR	  (100	  MHz,	  CDCl3,	  
30	   °C,	   TMS)	   δ	   10.8	   (CH3),	   11.6	   (CH3),	   14.2	   (CH3),	   18.0	   (CH2),	  
23.1	  (CH2),	  25.2	  (CH2),	  32.9	  (CH2),	  36.3	  (CH),	  56.9	  (CH2),	  121.8	  
(CH),	  122.9	  (C),	  127.8	  (C),	  140.1	  (CH);	  IR	  (KBr/cm-­‐1)	  1670	  (C=C),	  
1456,	   1219	   (NO2).	   HRMS	   (EI,	   double	   focusing)	  m/z	   calcd.	   for	  
C13H22N2O2:	  238.1681,	  found	  238.1689.	  	  
1,4-­‐Dihydro-­‐4-­‐isobutyl-­‐3-­‐isopropyl-­‐5-­‐nitro-­‐1-­‐propylpyridine	  
(5Ag)	  	  
Orange	  oil;	  1H	  NMR	  (400	  MHz,	  CDCl3,	  30	  °C,	  TMS)	  δ	  0.85	  (d,	  J	  =	  
6.8	  Hz,	  3H),	  0.92	  (d,	  J	  =	  6.8	  Hz,	  3H),	  0.95	  (t,	  J	  =	  7.6	  Hz,	  3H),	  1.07	  
(d,	  J	  =	  6.8	  Hz,	  3H),	  1.10	  (d,	  J	  =	  6.8	  Hz,	  3H),	  1.21–1.35	  (m,	  1H),	  
1.37–1.44	  (m,	  1H),	  1.54–1.73	  (m,	  3H),	  2.38–2.49	  (m,	  1H),	  3.29–
3.39	  (m,	  2H),	  3.91	  (t,	  J	  =	  4.4	  Hz,	  1H),	  5.72	  (s,	  1H),	  7.87	  (s,	  1H);	  
13C	  NMR	  (100	  MHz,	  CDCl3,	  30	  °C,	  TMS)	  δ	  10.8	  (CH3),	  20.6	  (CH3),	  
22.2	   (CH3),	   23.1	   (CH3),	   23.2	   (CH2),	   23.8	   (CH3),	   25.3	   (CH),	   30.2	  
(CH),	   33.5	   (CH),	   43.9	   (CH2),	   57.1	   (CH2),	   120.9	   (CH),	   124.2	   (C),	  
133.4	   (C),	   139.7	   (CH);	   IR	   (KBr/cm-­‐1)	   1670	   (C=C),	   1456,	   1211	  
(NO2).	   HRMS	   (EI,	   double	   focusing)	  m/z	   calcd.	   for	   C15H26N2O2:	  
266.1994,	  found	  266.1998.	  	  
1-­‐(tert-­‐Butyl)-­‐1,4-­‐dihydro-­‐3,5-­‐dinitro-­‐4-­‐(4-­‐
methylphenyl)pyridine	  (3Ba)	  	  
Orange	   solid	   (58.7	   mg,	   74%):	   mp	   277–278	   °C;	   1H	   NMR	   (400	  
MHz,	  CDCl3,	  30	  °C,	  TMS)	  δ	  1.60	  (s,	  9H),	  2.29	  (s,	  3H),	  5.61	  (s,1H),	  
7.09	  (d,	  J	  =	  8.0	  Hz,	  2H),	  7.17	  (d,	  J	  =	  8.0	  Hz,	  2H),	  8.15	  (s,	  2H);	  13C	  
NMR	   (100	  MHz,	   CDCl3,	   30	   °C,	   TMS)	   δ	   21.1	   (CH3),	   29.3	   (CH3),	  
39.3	   (CH),	   60.3	   (C),	   128.1	   (CH),	   129.2	   (CH),	   131.5	   (CH),	   133.7	  
(C),	  137.6	   (C),	  137.8	   (C);	   IR	   (KBr/cm-­‐1)	  1668	   (C=C),	  1497,	  1269	  
(NO2).	   HRMS	   (ESI,	   TOF)	   m/z	   calcd.	   for	   C16H20N3O4	   (M+H)
+:	  
318.1454,	  found	  318.1457.	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1-­‐(tert-­‐Butyl)-­‐1,4-­‐dihydro-­‐3,5-­‐dinitro-­‐4-­‐(4-­‐
methoxyphenyl)pyridine	  (3Bb)	  	  
Orange	   solid	   (50.0	   mg,	   60%):	   mp	   273–274	   °C;	   1H	   NMR	   (400	  
MHz,	  CDCl3,	  30	  °C,	  TMS)	  δ	  1.59	  (s,	  9H),	  3.77	  (s,	  3H),	  5.60	  (s,1H),	  
6.82	  (d,	  J	  =	  8.4	  Hz,	  2H),	  7.21	  (d,	  J	  =	  8.4	  Hz,	  2H),	  8.15	  (s,	  2H);	  13C	  
NMR	  (100	  MHz,	  CDCl3,	  30	  °C,	  TMS)	  δ	  29.3	  (CH3),	  38.9	  (CH),	  55.3	  
(CH3),	   60.3	   (C),	   114.0(CH),	   129.4	   (CH),	   131.4	   (CH),	   132.8	   (C),	  
133.7	  (C),	  159.3	  (C);	  IR	  (KBr/cm-­‐1)	  1668	  (C=C),	  1497,	  1269	  (NO2).	  
HRMS	   (EI,	   double	   focusing)	   m/z	   calcd.	   for	   C16H19N3O5:	  
333.1325,	  found	  333.1315.	  	  
1-­‐(tert-­‐Butyl)-­‐1,4-­‐dihydro-­‐3,5-­‐dinitro-­‐4-­‐phenylpyridine	  (3Bc)	  
Orange	   solid	   (65.2	   mg,	   86%):	   mp	   223–224	   °C;	   1H	   NMR	   (400	  
MHz,	  CDCl3,	  30	  °C,	  TMS)	  δ	  1.60	  (s,	  9H),	  5.65	  (s,1H),	  7.23–7.30	  
(m,	  5H),	  8.17	  (s,	  2H);	  13C	  NMR	  (100	  MHz,	  CDCl3,	  30	  °C,	  TMS)	  δ	  
29.3	   (CH3),	   39.7	   (CH),	   60.4	   (C),	   128.0	   (CH),	   128.3	   (CH),	   128.6	  
(CH),	  131.7	  (CH),	  133.6	  (C),	  140.4	  (C);	  IR	  (KBr/cm-­‐1)	  1670	  (C=C),	  
1487,	   1271	   (NO2).	   HRMS	   (EI,	   double	   focusing)	  m/z	   calcd.	   for	  
C15H17N3O4:	  303.1219,	  found	  303.1230.	  	  
1-­‐(tert-­‐Butyl)-­‐4-­‐(4-­‐chlorophenyl)-­‐1,4-­‐dihydro-­‐3,5-­‐
dinitropyridine	  (3Bd)	  	  
Orange	   solid	   (68.4	   mg,	   81%):	   mp	   248–249	   °C;	   1H	   NMR	   (400	  
MHz,	  CDCl3,	  30	  °C,	  TMS)	  δ	  1.60	  (s,	  9H),	  5.63	  (s,1H),	  7.23	  (d,	  J	  =	  
8.4	  Hz,	  2H),	  7.28	  (d,	  J	  =	  8.4	  Hz,	  2H),	  8.17	  (s,	  2H);	  13C	  NMR	  (100	  
MHz,	   CDCl3,	   30	   °C,	   TMS)	   δ	   29.3	   (CH3),	   39.3	   (CH),	   60.5	   (C),	  
128.8(CH),	   129.6	   (CH),	   131.8	   (CH),	   133.2	   (C),	   134.0	   (C),	   138.9	  
(C);	   IR	   (KBr/cm-­‐1)	   1670	   (C=C),	   1489,	   1271	   (NO2).	   HRMS	   (EI,	  




Brown	  solid	  (65.3	  mg,	  75%):	  mp	  220–221	  °C;	  1H	  NMR	  (400	  MHz,	  
CDCl3,	  30	  °C,	  TMS)	  δ	  1.62	  (s,	  9H),	  5.77	  (s,1H),	  7.49	  (d,	  J	  =	  8.4	  Hz,	  
2H),	  8.17	   (d,	   J	  =	  8.4	  Hz,	  2H),	  8.22	   (s,	  2H);	   13C	  NMR	  (100	  MHz,	  
CDCl3,	  30	  °C,	  TMS)	  δ	  29.3	  (CH3),	  40.0	  (CH),	  61.0	  (C),	  123.9	  (CH),	  
129.4	   (CH),	   132.4	   (CH),	   132.6	   (C),	   147.1	   (C),	   147.6	   (C);	   IR	  
(KBr/cm-­‐1)	   1670	   (C=C),	   1497,	   1271	   (NO2).	   HRMS	   (EI,	   double	  
focusing)	  m/z	  calcd.	  for	  C15H16N4O6:	  348.1070,	  found	  348.1078.	  	  
1-­‐(tert-­‐Butyl)-­‐1,4-­‐dihydro-­‐3,5-­‐dinitro-­‐4-­‐propylpyridine	  (3Bf)	  
Brown	   oil	   (17.6	   mg,	   26%);	   1H	   NMR	   (400	   MHz,	   CDCl3,	   30	   °C,	  
TMS)	   δ	   0.88	   (t,	   J	   =	   4.8	  Hz,	   3H),	   1.18	   (tq,	   J	  =	  4.8,	   8.5	  Hz,	   2H),	  
1.51	  (s,	  9H),	  1.65	  (dt,	  J	  =	  4.0,	  8.5	  Hz,	  2H)	  4.79	  (t,	  J	  =	  4.0	  Hz,	  1H),	  
8.10	   (s,	   2H);	   13C	   NMR	   (100	   MHz,	   CDCl3,	   30	   °C,	   TMS)	   δ	   13.9	  
(CH3),	  17.9	  (CH2),	  29.2	  (CH3),	  33.6	  (CH3),	  33.9	  (CH2),	  60.0	  (CH),	  
132.0	  (C),	  133.2	  (C);	  IR	  (KBr/cm-­‐1)	  1670	  (C=C),	  1489,	  1260	  (NO2).	  
HRMS	   (EI,	   double	   focusing)	   m/z	   calcd.	   for	   C12H19N3O4:	  
269.1376,	  found	  269.1384.	  	  
1-­‐(tert-­‐Butyl)-­‐1,4-­‐dihydro-­‐3,5-­‐dinitro-­‐4-­‐isobutylpyridine	  (3Bg)	  
Brown	   oil	   (22.7	   mg,	   32%);	   1H	   NMR	   (400	   MHz,	   CDCl3,	   30	   °C,	  
TMS)	  δ	  0.91	  (d,	  J	  =	  6.4	  Hz,	  6H),	  1.47–1.48	  (m,	  3H),	  1.52	  (s,	  9H),	  
4.78	  (t,	  J	  =	  5.2	  Hz,	  1H),	  8.07	  (s,	  2H);	  13C	  NMR	  (100	  MHz,	  CDCl3,	  
30	  °C,	  TMS)	  δ	  23.1	  (CH3),	  25.2	  (CH),	  29.3	  (CH3),	  31.8	  (CH),	  43.6	  
(CH2),	  60.0	  (C),	  132.9	  (CH),	  133.1	  (C);	  IR	  (KBr/cm
-­‐1)	  1653	  (C=C),	  
1506,	   1271	   (NO2)	   .	  HRMS	   (EI,	   double	   focusing)	  m/z	   calcd.	   for	  
C13H21N3O4:	  283.1532,	  found	  283.1531.	  
4-­‐(4-­‐Methoxyphenyl)-­‐3,5-­‐dinitropyridine	  (7)	  	  
Yellow	   solid	   (56.1	   mg,	   68%):	   mp	   139–140	   °C;	   1H	   NMR	   (400	  
MHz,	  CDCl3,	  30	  °C,	  TMS)	  δ	  3.86	  (s,	  3H),	  6.99	  (d,	  J	  =	  8.8	  Hz,	  2H),	  
7.19	  (d,	  J	  =	  8.8	  Hz	  2H),	  9.15	  (s,	  2H);	  13C	  NMR	  (100	  MHz,	  CDCl3,	  
30	   °C,	   TMS)	   δ	   55.4	   (CH3),	   114.9	   (CH),	   119.7	   (C),	   128.9	   (CH),	  
137.8	   (C),	  146.6	   (C),	  146.8	   (CH),	  161.4	   (C);	   IR	   (KBr/cm-­‐1)	  1539	  
(C=C),	  1360,	  1260	  (NO2).	  HRMS	  (EI,	  double	  focusing)	  m/z	  calcd.	  
for	  C12H9N3O5:	  275.0542,	  found	  275.0538.	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